Best Foundayo (Orforglipron) Providers in 2026 — Ranked & Reviewed
Foundayo (orforglipron) is the first FDA-approved oral GLP-1 receptor agonist for chronic weight management, approved on April 1, 2026 by Eli Lilly. Commercial dispensing started on April 6, 2026 and the provider list is small but growing fast. We track every US telehealth platform and pharmacy confirmed as a Foundayo channel, with pricing tiers verified directly from each provider's website. The Lilly Savings Card brings the price to $25/month for commercially insured patients, $149-$299/month for cash-pay. We update this list weekly as more providers come online.
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more
How we rank & what counts as “legit”
Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.
Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].
Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].
Quick Picks: Top 3
Detailed Reviews
LillyDirect Foundayo
Best for: patients with commercial insurance who want the cheapest legal brand-name GLP-1
Eli Lilly's manufacturer direct-pay channel for Foundayo (orforglipron), the first oral GLP-1 pill for weight loss. With the Lilly Savings Card, commercially insured patients pay $25/month; cash-pay patients pay $149-$299/month depending on labeled dose. Requires a valid US prescription from any licensed prescriber.
Score Breakdown
Pros
- ✓Cheapest legal path to a brand-name GLP-1 in 2026 ($25/mo with savings card for commercial insurance)
- ✓Direct from manufacturer — no compounding, no third-party reseller
- ✓Daily oral pill, no injections, no refrigeration
- ✓Available in all 50 states
Cons
- ✗Lower mean weight loss vs Wegovy (14.9%) and Zepbound (20.9%) — labeled-dose 11.1% per Foundayo PI
- ✗Requires existing prescription from a separate prescriber (LillyDirect does not write the prescription)
- ✗$25 savings card requires commercial insurance — Medicare and Medicaid not eligible
- ✗Strict empty-stomach 30-minute window may be hard for some patients to follow
WeightWatchers
Best for: community support + proven system
WeightWatchers combines its proven Points system with community workshops and, increasingly, GLP-1 clinical support. From $23/month digital to $99/month GLP-1 clinic, it offers the broadest tier range of any program on this list.
Score Breakdown
Pros
- ✓Most trusted brand — 70+ year history
- ✓In-person community workshops available
- ✓Multiple price tiers for every budget
- ✓GLP-1 clinic option for medication seekers
- ✓All 50 states
- ✓Highest accessibility score
Cons
- ✗Lower effectiveness without medication tier
- ✗App UX feels dated vs. newer competitors
- ✗Mixed user reviews across third-party sites
NowPatient
Best for: early adopters who want Foundayo via a one-stop telehealth platform
Telehealth platform offering Foundayo (orforglipron) prescriptions via online clinician consultation. Confirmed as a Foundayo channel via Endocrine News coverage of the April 2026 rollout. Pricing tier and full state availability TBD as the rollout matures.
Score Breakdown
Pros
- ✓Confirmed early Foundayo channel (April 2026 rollout)
- ✓Daily oral pill — no needles, no refrigeration
- ✓Telehealth consultation included
Cons
- ✗Pricing tier not yet publicly verified — confirm directly with the provider
- ✗State-by-state availability still being phased in
- ✗Lower mean weight loss vs injectable GLP-1s (~11.1% vs 14.9% Wegovy and 20.9% Zepbound at labeled max)
Related Rankings
Frequently Asked Questions
Sources & methodology — as of April 2026
- 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
- 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
- 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
- 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
- 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
- 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
- 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
- 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
- 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
- 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.